EGFR and Patent ductus arteriosus: Although it could be appealing to further investigate the combination of afatinib and capecitabine in KRASWT BTC patients based on these results, patient numbers were low, and previous larger randomized phase II studies (PICCA, Vecti-BIL, Taiwan Cooperative Oncology Group-TCOG did not demonstrate improvement in survival or responses with the addition of anti-EGFR monoclonal antibodies panitumumab or cetuximab to chemotherapy vs. chemotherapy alone in KRASWT BTC [44,45,46], albeit the phase III NOTABLE study with nimotuzumab added to gemcitabine in KRASWT PDA was positive [12].